cytarabine has been researched along with Critical Illness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatnagar, N; Greenough, A; James, B; Norton, A; O'Marcaigh, AS; Roberts, I; Tunstall, O; Vyas, P; Watts, T; Wright, M | 1 |
| Gadner, H; Koller, E; Krieger, O; Lutz, D; Schmitt, K; Schwarz, R; Tulzer, G; Zoubek, A | 1 |
2 other study(ies) available for cytarabine and Critical Illness
| Article | Year |
|---|---|
Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Cell Transformation, Neoplastic; Critical Illness; Cytarabine; DNA Mutational Analysis; Down Syndrome; Exchange Transfusion, Whole Blood; Female; Fetal Diseases; GATA1 Transcription Factor; Humans; Leukapheresis; Leukemoid Reaction; Liver Diseases; Mutation; Neoplasm, Residual; Pregnancy; Prenatal Diagnosis; Prognosis; Recurrence; Risk Factors | 2018 |
All-trans retinoic acid and short-time, high-dose cytarabine in two children with acute promyelocytic leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Agents; Child, Preschool; Critical Illness; Cytarabine; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Remission Induction; Syndrome; Tretinoin | 1996 |